Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Selumetinib in KRAS Mutant NSCLC
NCT03004105Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2018
- Primary completion
- May 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of selumetinib, durvalumab in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Planned start May 2018; status: withdrawn.
02
Drugs
selumetinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03004105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004105.